C WorldWide Group Holding A S Makes New $3.59 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

C WorldWide Group Holding A S purchased a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 95,000 shares of the company's stock, valued at approximately $3,587,000. C WorldWide Group Holding A S owned 0.07% of Vaxcyte at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Wells Fargo & Company MN boosted its position in Vaxcyte by 53.7% during the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock valued at $5,916,000 after purchasing an additional 25,257 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Vaxcyte by 5.5% during the first quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock worth $6,843,000 after purchasing an additional 9,416 shares during the period. Parallel Advisors LLC lifted its holdings in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after acquiring an additional 1,071 shares during the period. Pictet Asset Management Holding SA lifted its holdings in Vaxcyte by 30.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,017,845 shares of the company's stock valued at $83,321,000 after acquiring an additional 236,940 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in Vaxcyte by 37.3% in the fourth quarter. Russell Investments Group Ltd. now owns 108,389 shares of the company's stock valued at $8,873,000 after acquiring an additional 29,442 shares during the period. Hedge funds and other institutional investors own 96.78% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on PCVX shares. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Bank of America dropped their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. The Goldman Sachs Group decreased their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Finally, Cantor Fitzgerald assumed coverage on Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating on the stock. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Vaxcyte presently has a consensus rating of "Buy" and an average target price of $136.50.

Vaxcyte Price Performance

Vaxcyte stock traded down $0.47 during mid-day trading on Friday, hitting $36.90. 97,418 shares of the company were exchanged, compared to its average volume of 1,487,831. The company has a market capitalization of $4.76 billion, a P/E ratio of -9.26 and a beta of 1.19. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The business's 50 day simple moving average is $33.74 and its two-hundred day simple moving average is $54.16.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter last year, the firm earned ($0.85) earnings per share. Equities research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.